- On September 19, 2024, Lonza Group Ltd. inaugurated the Innovaform Accelerator, a dedicated oral drug product development center in Colmar, France. This facility is designed to support pharmaceutical partners with accelerated formulation and capsule-based drug development projects. The opening of this center marks a pivotal step in Lonza’s strategy to co-develop advanced therapeutic solutions and further solidifies its commitment to collaborative innovation in the global pharmaceutical softgel and hard capsule space.
- On June 20, 2024, Lonza Group Ltd. expanded its Capsugel Enprotect product line with the launch of Capsugel Enprotect Size 9 capsules. Specifically developed for rodent preclinical trials, this smaller format supports early-stage drug formulation and targeted intestinal delivery research. This strategic move emphasizes Lonza’s role in accelerating pharmaceutical innovation and extending its advanced capsule technologies into preclinical development settings, reinforcing its leadership in the global pharmaceutical encapsulation market.
- On November 1, 2022, Lonza Group Ltd. launched Capsugel Enprotect, a next-generation, coating-free enteric capsule designed to deliver acid-sensitive pharmaceutical ingredients directly to the intestine. This innovation reflects the company's ongoing commitment to enabling advanced drug delivery solutions and enhancing therapeutic outcomes. By removing the need for an external enteric coating, this launch streamlines the development process for oral dosage forms and strengthens Lonza’s position in the evolving softgel and hard capsule market.
